Rosiglitazone in associazione con antidiabetici orali: valutazione su outcome cardiovascolari lo studio RECORD
(Rosiglitazone Evaluated for Cardiovascular outcomes in Oral agent combination therapy for type 2 Diabetes)

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/130365 since

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)